



Decatylen®

Throat lozenges

Bacteriolytic and antimycotic with a broad spectrum of activity

Composition

Each lozenge contains:

Dequalinium chloride (BP) 0.25 mg

Dibucaine hydrochloride (USP) 0.03 mg

Properties

The highly bactericidal and fungistatic agent, dequalinium chloride, has a rapid effect even in high dilutions, on organisms causing mixed infections of the mouth and pharynx. The spectrum of activity of this local chemotherapeutic agent is very wide and includes gram+ and gram- bacteria and cocci as well as fungi and spirochaetes. Even bacterial strains which are resistant to antibiotics are eliminated. The added dibucaine hydrochloride produces mild local anaesthesia, which relieves the painful symptoms accompanying mouth and throat infections.

Indications

Painful infections of the mouth and throat.

Anginous infections: Angina catarrhalis, as adjuvant in angina lacunaris and Plaut-Vincent's angina.

Catarrhal infections:

Pharyngitis, laryngitis.

Inflammations of the mucous membrane and gums: Gingivitis, ulcerative stomatitis, aphthous stomatitis.

Candidiasis of the buccopharyngeal cavity.

Post-operative application following tonsillectomy and dental extractions, to promote smooth healing.

Prophylaxis in times of increased infections.

Dosage

Adults and children: Allow 1 lozenge to dissolve slowly in the mouth every 2 hours. After the inflammatory symptoms have subsided, suck 1 lozenge every 4 hours.

Contraindications

None known.

Side effects

Side effects and undesirable accompanying symptoms have not been observed.

Interactions with other drugs

None known.

Tolerance

Decatylen lozenges are very histotropic. They cause neither irritation nor allergy. The mucous membranes remain moist, which promotes the healing process. As the active compound is hardly absorbed, no repercussions on the internal organs, blood or central nervous system need be feared. Likewise teratogenicity need not be dreaded. Dequalinium chloride does not affect the intestinal flora.

Special features

As Decatylen does not cause the development of resistant organisms, it can be administered repeatedly with equal therapeutic success.

Presentation

Packings of 20 lozenges

Hospital packings

The information contained here is limited. Further information can be obtained from your doctor or pharmacist.

mepha

Mepha Ltd
Aesch-Basel
Switzerland

4 03 07 1 202
5294